Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. - Publication

Publication

Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.

Journal Paper/Review - Sep 7, 2023

Schmidt Marcus, Nitz Ulrike A, Reimer Toralf, Schmatloch Sabine, Graf Heiko, Just Marianne, Stickeler Elmar, Untch Michael, Runnebaum Ingo B, Belau Antje, Huober Jens, Jackisch Christian, Hofmann Manfred, Krocker Jutta, Nekljudova Valentina, Loibl Sibylle, GBG/AGO-B, NOGGO/WSG study groups

Citation

Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer 2023; 194:113324.

Type

Journal Paper/Review (English)

Journal

Eur J Cancer 2023; 194

Publication Date

Sep 7, 2023

Issn Electronic

1879-0852

Pages

113324

Brief description/objective

Evaluation of the impact of a de-escaleted chemotherapy regimen consisting of capecitabine (Cap) on invasive disease-free survival (iDFS) in patients ≥65 years with node-positive/high-risk node-negative early breast cancer (BC) receiving ibandronate (Ib).